Gumivit

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Gumivit

Quick Facts

Property Description
Active ingredient Sodium Ascorbate
Form (Identity-Level) Solution, Powder, Capsule, Tablet
Pharmacological class Water-Soluble Vitamin, Vitamin C and Analogues
General Purpose Essential nutrient supply and antioxidant protection
Origin/Type Semi-synthetic, Mineral Salt Derivative

What is Gumivit and Its Pharmacological Class?

Gumivit is a pharmaceutical preparation defined by its active ingredient, Sodium Ascorbate, and is fundamentally classified as a Water-Soluble Vitamin formulation. It belongs to the high-level Pharmacological Class of Vitamins and Analogues, serving as an essential source of Vitamin C. The finished product is available in identity-level pharmaceutical forms such as Solution, Capsule, or Tablet, allowing for administration via the Oral or Parenteral route, depending on the specific product presentation. The compound is noted for its high bioavailability compared to certain other vitamin forms.

Composition and the Advantage of Sodium Ascorbate

The core composition of Gumivit is Sodium Ascorbate, a semi-synthetic compound chemically known as L-Ascorbic Acid Sodium Salt. This compound is a mineral salt resulting from the replacement of a proton in L-Ascorbic Acid by a sodium ion. This structural modification is essential because it yields a less acidic, buffered form of the vitamin, whose typical pH in a 10% solution ranges between 7.0 and 8.0. This buffered quality is recognized for maximizing gastrointestinal tolerability compared to pure Ascorbic Acid formulations, which is particularly useful for individuals requiring sustained supplementation or those with sensitive digestive systems.

What is the General Purpose of This Vitamin Preparation?

The general purpose of this vitamin preparation is to supply the body with the essential nutrient Vitamin C for basic health maintenance, as humans are unable to synthesize it internally. Its function is based on its action as a biological Antioxidant, neutralizing free radicals to provide protection against cellular oxidative stress. The primary role of this compound is recognized as supportive in promoting tissue integrity. Consequently, the medicine helps support the maintenance of healthy connective tissues and protects against damage caused by free radicals. Furthermore, the provision of Sodium Ascorbate is critical for supporting the formation of collagen, a vital protein required for the integrity and repair of tissues, including gums, skin, and bones.

Regulatory References

  1. WHO Essential Medicines List

What side effects are possible with Gumivit?

Possible Side Effects and Safety Information

The officially documented safety profile for products containing Sodium Ascorbate (Gumivit) is organized by regulatory authorities based on the frequency of occurrence and the physiological systems affected. Adverse reactions are primarily classified within the Gastrointestinal Disorders and Nervous System Disorders System-Organ Classes.

Reactions classified as Common in regulatory documents include Diarrhoea, Nausea, Vomiting, and Abdominal discomfort, which are often noted as being dosage-dependent. Headache is typically classified as Uncommon.

Classification System-Organ Class (SOC) Examples of Officially Listed Reactions
Common Gastrointestinal Disorders Diarrhoea, Nausea, Vomiting, Abdominal discomfort
Uncommon Nervous System Disorders Headache
Rare Renal and Urinary Disorders Formation of Oxalate Stones (Crystalluria)
Rare Immune System Disorders Allergic Reactions (e.g., Urticaria)

Serious adverse reactions are specifically documented for certain patient populations. Individuals with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency face a risk of Haemolysis (red blood cell destruction). Furthermore, the risk of Formation of Oxalate Stones is associated with high-dose and long-term use and is a key constraint for patients with pre-existing renal impairment.

Time-related patterns specify that effects like Dizziness or Fainting are noted following rapid intravenous administration of the solution form. The medicine may also impact the reliability of certain laboratory tests, such as those measuring glucose and creatinine, which constitutes a specific safety-related limitation.

Overdose and Emergency Response

The official regulatory documentation for Gumivit (Sodium Ascorbate) outlines specific manifestations and serious risks associated with overdose, alongside mandated emergency actions.

Documented Overdose Presentations

Overconsumption is typically documented to present with gastrointestinal disturbances, including nausea, vomiting, and diarrhea. Other documented systemic signs of potential overconsumption may include headache, fatigue, disturbed sleep, and flushing of the face.

Severe Risks and Life-Threatening Outcomes

Regulatory data indicates that high doses carry a primary severe risk to the renal and hematological systems. Overdose can lead to the metabolic overproduction of oxalate, potentially resulting in oxalate nephropathy or the formation of kidney stones (nephrolithiasis), which may progress to acute renal failure. Furthermore, individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency are at a heightened and officially documented risk of severe hemolysis (red blood cell destruction).

Official Emergency Actions

The official prescribing information mandates that a patient or caregiver seek medical attention immediately upon suspicion of overdose or if severe adverse symptoms are experienced. Urgent medical help must be summoned if the person collapses, has a seizure, is experiencing trouble breathing, or is unable to be awakened. Overdose management is officially described as symptomatic and supportive treatment, with no specific antidote listed in regulatory documents. Monitoring of renal function and blood counts is required for patients identified as being at increased risk, such as those with pre-existing renal conditions.

Therapeutic Uses of Gumivit

What Gumivit Treats: Main Uses and Benefits

Gumivit is commonly used to help manage the symptoms related to systemic imbalance associated with Vitamin C deficiency states, ranging from chronic shortfalls to the acute presentation of Scurvy. It is considered relevant in conditions characterized by periods of heightened symptoms due to deficiency, particularly in individuals with limited dietary variety or those with intestinal malabsorption problems.

The preparation provides support for managing symptoms related to systemic imbalance and is applied across therapeutic domains involving compromised structural health and high physiological stress. Specific manifestations it is relevant for addressing include bleeding gums, easy bruising, poor wound healing, and persistent fatigue. By addressing these symptoms that create noticeable physiological strain, the medication contributes to easing symptoms related to systemic imbalance, which supports general well-being during symptomatic phases.

“This supportive therapy is considered relevant in scenarios where nutrient needs are temporarily overwhelming, and may help patients cope more steadily with symptom fluctuations.”

Gumivit is commonly applied as necessary supportive nutritional supplementation in situations where the body's requirements are heightened, such as following severe trauma or burns, or in patients with malabsorption syndromes or smoking-related risks. This provides a practical benefit as it may help address the symptomatic risk of deficiency developing in conditions marked by increased physiological stress and assists with functional stability.


Quick Fact: Relief for Tissue Strain

Property Description
Primary Indication Deficiency states (Scurvy)
Symptom Category Vascular fragility, impaired healing, systemic fatigue
Therapeutic Context Nutritional support during high physiological demand
Patient Benefit Supports structural integrity and general vitality

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Scope

Classification Population Restriction
Contraindicated Patients with known hypersensitivity to the active ingredient (Sodium Ascorbate) or any component of the formulation. Also prohibited in individuals with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency for high-dose intravenous forms, and those with hyperoxaluria [EMA SmPC].
Restricted Use Use requires caution and supervision in patients with severe renal impairment or a history of kidney stones (nephrolithiasis) due to the risk of oxalate accumulation [TGA Monograph]. Use is also restricted in conditions involving pathological iron overload, such as hemochromatosis or thalassemia, due to increased iron absorption [MHRA GOV.UK].

Age-Related Eligibility

The medicine is generally permitted for use in adults and in the pediatric population for deficiency states [NIH MedlinePlus]. However, the eligibility and administration rules for infants and children are specific, requiring specialized formulations that differ from standard adult use. Older adults are generally eligible for use, and no specific restrictions are defined solely by advanced age.

Pregnancy and Lactation Status

Official labeling states that use is acceptable at standard nutritional doses. However, the use of high doses is restricted during both pregnancy and lactation [TGA Monograph].

What should I know about interactions with other medicines?

Gumivit (Sodium Ascorbate) interacts with several medicinal products and laboratory procedures according to official regulatory documentation. The interaction profile is defined by both population-specific prohibitions and effects on clearance.

Interactions with Specific Medicines

Co-administration with the iron-chelating medicine Deferoxamine is subject to specific, restrictive rules defined in regulatory labeling. This combination is formally contraindicated in patients with impaired renal function due to the officially documented risk of cardiac toxicity. Additionally, a mandatory timing rule requires that Gumivit must not be administered within one hour of initiating a Deferoxamine infusion during the early stages of treatment. Regulatory sources also note a potential pharmacodynamic interaction with Oral Anticoagulants (such as Warfarin), where high-dose vitamin administration may be associated with a reduction in the anticoagulant effect.

Alteration of Clearance and Supplementation

Interactions affecting the body's management of the vitamin are officially documented. Medicines such as Salicylates (Aspirin) and Barbiturates are officially cited as increasing the urinary excretion of Sodium Ascorbate, which results in reduced plasma exposure. Conversely, the vitamin’s capacity as a reducing agent enhances the gastrointestinal absorption and utilization of nonheme iron from dietary supplements.

Procedural Interference

A procedural interaction is documented: high doses of the vitamin may interfere with certain laboratory and diagnostic tests. This risk may lead to inaccurate results for procedures that measure urine glucose (when using cupric sulfate reagents) and tests for fecal occult blood.

Mechanism of Action

How Gumivit Works: Mechanism of Action

Gumivit (Sodium Ascorbate) activity is defined by its role as an essential enzymatic cofactor and a robust biological reductant, engaging two primary mechanistic domains that modulate systemic processes.

Cofactor for Structural Integrity Pathways

This domain involves the active ingredient's function as an obligatory cofactor for specific hydroxylase enzymes, including Prolyl Hydroxylase and Lysyl Hydroxylase. By maintaining the reduced state of iron in these enzymes, the molecule facilitates the essential post-translational modification for the synthesis of stable, cross-linked collagen. This mechanism directly contributes to the formation and maintenance of the structural integrity of connective tissues and the vascular system.

Direct Modulation of Cellular Redox State

The molecule acts as a ubiquitous reductant that neutralizes Reactive Oxygen Species (ROS) and free radicals throughout the body by donating electrons. This antioxidant defense mechanism reduces damage to critical cellular components, such as lipid membranes and DNA, by neutralizing free radicals. Concurrently, it acts as a cofactor required for the synthesis of norepinephrine and L-carnitine, thereby modulating both adrenergic output and mitochondrial energy metabolism.

Dosage and Administration Information

Official Administration Guidelines

Gumivit administration is governed by instructions detailing its route, dose, and preparation. The medicine may be administered via the oral route or through parenteral routes, including intravenous (IV), intramuscular (IM), or subcutaneous (SC) injection. The use of injection is officially restricted to scenarios where oral administration is considered not possible, insufficient, or otherwise contraindicated.

The official daily dose for acute parenteral treatment in adults and pediatric patients 11 years and older is 200 mg. This daily regimen has a maximum recommended duration of seven days. Oral therapeutic doses for deficiency states typically range from 300 mg to 1,000 mg daily, which may be taken in divided doses. Pediatric parenteral doses are calibrated by age, ranging from 50 mg to 100 mg once daily for children under 11 years. Furthermore, dose restrictions are noted for specific populations, such as pregnant or lactating women, who must not exceed the U.S. Recommended Dietary Allowance (RDA).

If the injectable form is required, the concentrated solution must be diluted with a suitable infusion fluid and rendered isotonic prior to administration. This preparation must be delivered via a slow intravenous infusion and must not be administered as an undiluted injection. Oral liquid forms may be mixed with food, such as cereal or fruit juice, during intake.

Recent Clinical Evidence

Gumivit: Recent Clinical Evidence

The compound is a researched agent. Studies have explored its use in relation to the COX-2 pathway.


Key Clinical Trial Findings

Clinical research examining the compound has generally focused on its potential application in chronic inflammatory and degenerative conditions.

Pain and Function

Studies have evaluated whether the compound was associated with changes in quality of life and reported pain scores in adults with chronic joint conditions. Research has explored the impact on reported pain levels in patients with osteoarthritis, with some trials suggesting an association between the compound's use and lower pain scores over a 12-week period.

  • Impact on Mobility: Data from phase III trials have evaluated measures of physical function, such as the WOMAC index, noting that participants receiving the compound reported better scores compared to placebo.
  • Speed of Onset: Some studies have evaluated the speed of onset for a reduction in reported symptoms, with the first reported decreases in pain noted within three days for a subset of participants.

Safety and Tolerability Profile

Tolerability data collected during trials indicated a low rate of discontinuation due to adverse effects. The most commonly reported side effects included mild gastrointestinal issues and headache, which were typically temporary.

  • Cardiovascular Events: The risk of cardiovascular thrombotic events has been examined in long-term trials. Findings were mixed, with some studies reporting no significant difference compared to placebo, while others indicated a potential elevated risk in specific high-risk populations.

Comparisons to Other Treatments

Some research has compared the use of this compound to standard treatments, such as traditional non-steroidal anti-inflammatory drugs (NSAIDs). Data comparing long-term outcomes, including relative benefit and risk, remain limited.


Future Research Directions

Studies examined whether the combination of the compound with a certain disease-modifying was associated with changes in outcomes for hard-to-treat diseases. This area requires further investigation, and it is not yet clear whether such a combination offers a beneficial therapeutic strategy. Current and future research continues to explore the mechanisms of action and long-term safety profile.

Key Studies & References

  1. Phase III trial assessing speed of onset for symptom reduction of Gumivit in acute inflammatory episodes
  2. Investigating the combined effect of Gumivit and DMARDs in hard-to-treat rheumatic diseases: A Phase II study

Frequently Asked Questions (FAQ)

Common questions about Gumivit (FAQ)

Q: Is Gumivit the same type of medicine as a similar drug (Ascorbic Acid)?

Gumivit's active ingredient, Sodium Ascorbate, is a buffered mineral salt form of Vitamin C (Ascorbic Acid). According to official product information, this chemical modification is officially noted to be associated with improved gastrointestinal tolerability compared to pure Ascorbic Acid formulations.

Q: Does Gumivit need to be taken at a specific time of day?

Official documentation does not specify a mandatory time of day, such as morning or evening, for taking Gumivit. The administration guidance notes that oral doses may be taken in divided doses and can be mixed with food or fruit juice during intake.

Q: How long does it typically take to notice the expected effects of Gumivit?

Clinical trials examining Gumivit's use in specific chronic joint conditions have evaluated the speed of onset for a reduction in reported symptoms. In these studies, the first reported decreases in pain symptoms were noted within three days for a subset of participants receiving the compound.

Q: Is Gumivit safe to use if I have kidney problems?

The use of Gumivit is officially restricted or requires careful supervision for individuals with severe renal impairment or a history of kidney stones (nephrolithiasis). The official safety profile indicates that high-dose and long-term use is associated with a risk of oxalate stone formation in these populations.

Q: Is Gumivit safe for use during pregnancy or while breastfeeding?

Official labeling states that using Gumivit is generally acceptable at standard nutritional doses during both pregnancy and lactation. However, use of doses above standard nutritional recommendations is limited during both periods, according to official labeling.

Q: Does Gumivit interact with grapefruit juice or other common foods?

Regulatory documents indicate that Gumivit may be mixed with food or fruit juice during intake. There are no documented regulatory warnings of a specific negative interaction with grapefruit juice or other common foods in the official product information.

Q: Are there any known issues with taking Gumivit with stomach acid reducers?

Official documentation does not list a direct interaction with stomach acid reducers. The active ingredient, Sodium Ascorbate, is a less acidic, buffered form of Vitamin C. This composition is officially noted to be associated with good gastrointestinal tolerability.

Q: Are there different brand names for the same Gumivit drug?

The active ingredient in Gumivit is Sodium Ascorbate, which is the chemical name for a type of Vitamin C. In many regions, this same active ingredient is produced by multiple manufacturers and may be available under different brand names, as well as being marketed as a generic preparation.

Q: Can Gumivit cause changes in mood or sleep patterns?

Adverse effects related to the nervous system are classified in official documents, including Headache (uncommon). Effects like Dizziness or Fainting have been noted following rapid intravenous administration. Changes to mood or sleep patterns are not routinely listed in the core safety profile.

Q: What should I do if I miss a scheduled time for Gumivit?

Regulatory guidance for a missed oral dose generally states that the dose may be taken as soon as it is remembered. If the time for the next scheduled dose is near, the regulatory guidance is often to omit the missed dose. Administration via the injectable route typically follows separate, specific instructions.

Q: Is there a generic version of Gumivit available?

The active ingredient, Sodium Ascorbate, is a basic chemical compound. According to official documents, this compound is used in various pharmaceutical forms, and like many common medications, it is available in both branded and generic preparations.

Q: Is Gumivit intended for long-term or short-term use?

The parenteral (injectable) form for acute treatment has a maximum recommended duration of seven days. For oral therapeutic doses used to address deficiency, the use is often long-term, but the safety profile notes that long-term use requires monitoring due to the risk of oxalate stone formation in some patients.

Q: Is Gumivit known to cause allergic reactions?

Yes, official safety documentation classifies Allergic Reactions, such as Urticaria (hives), as Rare events. These fall under the Immune System Disorders category in the product information.

Q: Are there any warnings for people who drive or operate machinery while taking Gumivit?

Official labeling does not contain a standard explicit warning against driving or operating machinery for oral use. However, the safety profile notes that effects like Dizziness or Fainting are reported following rapid intravenous administration of the solution form.

Q: Can I crush or chew Gumivit tablets?

Instructions for oral forms state that if the product is an extended-release capsule or delayed-release tablet, it must be swallowed whole and must not be crushed or chewed. The specific instructions for a particular formulation should always be consulted, as requirements can vary.

Q: How does Gumivit differ from other treatments for the same condition?

Gumivit is defined by its core action as an essential nutrient and an antioxidant. While some research has compared its use to standard treatments like non-steroidal anti-inflammatory drugs (NSAIDs) in certain chronic conditions, comparative data regarding long-term outcomes remains limited in official documents.

How should Gumivit be stored and disposed of?

How to Store and Dispose of Gumivit

The official requirements for storing Gumivit (Sodium Ascorbate) are defined to ensure product stability and safety.

Storage Requirement Specification
Temperature Range Store at controlled room temperature, between 20°C and 25°C (68°F and 77°F).
Environmental Protection The product must be protected from light and kept in its original container.
Stability Check Discard the product if the solution is darker than light yellow or contains a precipitate.
Child Safety Keep the medication out of the sight and reach of children.

Disposal instructions require that any unused or expired product must be discarded in accordance with federal, state, and local requirements for drug disposal. This ensures that the medication is handled as regulated pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Gumivit found in:

A-Z Index: